Amphastar Pharmaceuticals, Inc. (AMPH)

US — Healthcare Sector
Peers: COLL  EGRX  ALKS  EOLS  NBIX  IRWD  ANIP  PBH  DCPH  PCRX  PAHC  EVO  SUPN 

Automate Your Wheel Strategy on AMPH

With Tiblio's Option Bot, you can configure your own wheel strategy including AMPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AMPH
  • Rev/Share 15.2865
  • Book/Share 15.7697
  • PB 1.6373
  • Debt/Equity 0.8686
  • CurrentRatio 2.9538
  • ROIC 0.1112

 

  • MktCap 1217131562.0
  • FreeCF/Share 3.1533
  • PFCF 8.1019
  • PE 8.6854
  • Debt/Assets 0.4012
  • DivYield 0
  • ROE 0.1937

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade AMPH JP Morgan Overweight Neutral -- $30 May 12, 2025
Downgrade AMPH Piper Sandler Overweight Neutral $66 $36 Feb. 4, 2025

News

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
AMPH
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Read More
image for news Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
AMPH
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Read More
image for news Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
AMPH
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
AMPH
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.

Read More
image for news Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
AMPH
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.

Read More
image for news Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
AMPH
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Read More
image for news Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
AMPH
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Read More
image for news Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
New Strong Sell Stocks for March 24th
AIRS, AMPH, AVNS
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Negative

AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.

Read More
image for news New Strong Sell Stocks for March 24th
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
AMPH
Published: February 28, 2025 by: Benzinga
Sentiment: Negative

On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.

Read More
image for news Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Amphastar: Earnings Miss, Margins Drop
AMPH
Published: February 28, 2025 by: The Motley Fool
Sentiment: Negative

Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Read More
image for news Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
AMPH
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a …

Read More
image for news Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
AMPH
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH
AMPH
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.

Read More
image for news Investors who Lost Money on Amphastar Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - AMPH
Amphastar Pharmaceuticals: A Gradual Strategy
AMPH
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive

Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside.

Read More
image for news Amphastar Pharmaceuticals: A Gradual Strategy
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH)
AMPH
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Amphastar Pharmaceuticals, Inc. ("Amphastar Pharmaceuticals, Inc.") (NASDAQ:AMPH) concerning possible violations of federal securities laws. On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug.

Read More
image for news Levi & Korsinsky Investigates Possible Securities Fraud Violations by Amphastar Pharmaceuticals, Inc. (AMPH)

About Amphastar Pharmaceuticals, Inc. (AMPH)

  • IPO Date 2014-06-25
  • Website https://www.amphastar.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Dr. Yongfeng Zhang Ph.D.
  • Employees 2028

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.